Non-Royalty Sublicensing Income Sample Clauses

Non-Royalty Sublicensing Income. Company shall pay Wistar [**] percent ([**]%) of Non-Royalty Sublicensing Income within [**] ([**]) days following the last day of the Calendar Quarter in which such Non-Royalty Sublicensing Income accrues.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Non-Royalty Sublicensing Income. (a) Licensee shall pay APL on the following graduated scale for NRSI received from each sublicensee, on a per sublicensee basis, for any NRSI that includes an Licensed Analytic Product or Licensed Service:
Sample 1Sample 2Sample 3
Non-Royalty Sublicensing Income. Licensee shall pay APL a percentage of all NRSI according to the following schedule: [To be determined]
Sample 1Sample 2
Non-Royalty Sublicensing Income. COMPANY shall pay HOSPITAL within thirty (30) days of receipt thereof a percentage of any and all non-royalty income paid to COMPANY or an AFFILIATE in consideration for the sublicensing of any license granted hereunder, including but not limited to [***]) (“NON-ROYALTY INCOME PERCENTAGE”). Said NON-ROYALTY INCOME PERCENTAGE shall depend upon the time at which COMPANY or an AFFILIATE executes the agreement with a third party providing for such non-royalty income (“THIRD PARTY AGREEMENT”) as follows. In the event the THIRD PARTY AGREEMENT is executed:
Sample 1Sample 2
Non-Royalty Sublicensing Income. Subject to the terms of this Section 8.6, Tautomer shall pay Skye [***] percent ([***]%) of all Non-Royalty Sublicensing Income received by Tautomer or its Affiliates from Sublicensees. For clarity, to avoid double-counting of payments, Tautomer and its Affiliates shall have the right to credit the amounts of any milestone payment owed to Skye under Section 8.3 or Section 8.4 against any Non-Royalty Sublicensing Income arising from any payment received by Tautomer or its Affiliates from a Sublicensee for achievement of the substantially equivalent milestone event, prior to the calculation of the share of Non-Royalty Sublicensing Income payable to Skye. Within thirty (30) days after receipt of any Non-Royalty Sublicensing Income by Tautomer or its Affiliates, Tautomer shall notify Skye in writing and portion of Non-Royalty Sublicensing Income payable to Skye under this Section 8.6.
Sample 1
Non-Royalty Sublicensing Income. Company shall pay to UC [*] ([*]%) of all Non-Royalty Sublicense Income.
Sample 1
Non-Royalty Sublicensing Income. The following percentage of any and all other consideration (including any premium above fair market value for debt and/or equity securities or instruments, or the market value of an arm’s-length transaction of any cross-licensing rights granted by Sublicensee to Company), including without limitation, any upfront, milestone or lump sum payments (including but are not limited to payments for the achievement of patent, pre-clinical, clinical, regulatory, sales or any other milestone), and/or fair market value of any non-cash consideration, received by Company from Sublicensees, their Designees or their Affiliates as full or partial consideration for the grant of any sublicense (or any option or any right to negotiate for sublicense) by Company under Section 2b of this Agreement (“Non-Royalty Sublicensing Income” or “NRSI”): Event Percentage (%) of Non-Royalty Sublicensing Income [***] [***]% of NRSI [***] [***]% of NRSI [***] [***]% of NRSI NRSI shall not include any of the following: (a) royalties on Net Sales of Products; (b) payments by Sublicensees, Designees or any Affiliates of the foregoing for payment or reimbursement of patent prosecution, defense, enforcement or maintenance expenses in respect of the Patents; (c) the fair market value of payments received by Company from a Sublicensee for any debt and/or equity securities or instruments issued by Company, or payments for an acquisition of all or substantially all of its assets that include the assignment of this Agreement; and (d) funds received from a Sublicensee, Designee or any Affiliate of the foregoing for bona fide research and development of Products (including payments for FTEs), which research and development is conducted after the actual date of execution of the Sublicense. To the extent that patent rights, other intellectual property rights or other rights or obligations other than Patents, Technical Information or Materials are licensed, sublicensed or granted by Company, that portion of the consideration received by Company shall be equitably apportioned between the Patents, Technical Information and Materials and those other rights and obligations, and such apportionment shall be reasonable and in accordance with customary standards in the industry. In the event that Columbia disagrees, in good faith, with Company’s apportionment, the Parties will meet and discuss in good faith and if the Parties are unable to reach agreement on the apportionment, the issue will be submitted to a neu...
Sample 1
AutoNDA by SimpleDocs
Non-Royalty Sublicensing Income. To the extent that CardioDx is required to make any payment to UC for Non-Royalty Sublicensing Income (as defined in the UC Licenses) resulting from any payments made pursuant to this Agreement or pursuant to any agreement that sublicenses any rights granted under this Agreement, then ARCA shall pay to CardioDx the amount of any such payments on the date that any such payments are due from CardioDx to UC.
Sample 1
Non-Royalty Sublicensing Income. Company shall pay to Wistar *** percent (***%) of Non-Royalty Sublicensing Income within thirty (30) days following the last day of the Calendar Quarter in which such Non-Royalty Sublicensing Income is paid to or received by the Company accrues in a form that can be chosen at the Wistar’s option, including the form in which Company received or was paid such Non-Royalty Sublicensing Income, provided that if Wistar elects a form other than the form in which the Company received or was paid Non-Royalty Sublicensing Income, that Wistar and the Company will share equally the cost of converting the Non-Royalty Sublicensing Income received to the form that Wistar elects.
Sample 1

Related to Non-Royalty Sublicensing Income

  • Sublicense Revenue In the event Licensee or an Affiliate of Licensee sublicenses under Section 2.2, Licensee shall pay CareFusion **THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION.** of any Sublicense Revenues resulting from sublicense agreements executed by Licensee.

  • Sublicense Income Company shall pay Medical School {***} of all Sublicense Income. Such amounts shall be due and payable within sixty (60) days after Company receives the relevant payment from the Sublicensee.

  • Running Royalties Company shall pay to JHU a running royalty as set forth in Exhibit A, for each LICENSED PRODUCT(S) sold, and for each LICENSED SERVICE(S) provided, by Company or AFFILIATED COMPANIES, based on NET SALES and NET SERVICE REVENUES for the term of this Agreement. Such payments shall be made quarterly. All non-US taxes related to LICENSED PRODUCT(S) or LICENSED SERVICE(S) sold under this Agreement shall be paid by Company and shall not be deducted from royalty or other payments due to JHU. In order to insure JHU the full royalty payments contemplated hereunder, Company agrees that in the event any LICENSED PRODUCT(S) shall be sold to an AFFILIATED COMPANY or SUBLICENSEE(S) or to a corporation, firm or association with which Company shall have any agreement, understanding or arrangement with respect to consideration (such as, among other things, an option to purchase stock or actual stock ownership, or an arrangement involving division of profits or special rebates or allowances) the royalties to be paid hereunder for such LICENSED PRODUCT(S) shall be based upon the greater of: 1) the net selling price (per NET SALES) at which the purchaser of LICENSED PRODUCT(S) resells such product to the end user, 2) the NET SERVICE REVENUES received from using the LICENSED PRODUCT(S) in providing a service, or 3) the net selling price (per NET SALES) of LICENSED PRODUCT(S) paid by the purchaser. No multiple royalties shall be due or payable because any LICENSED PRODUCT(S) or LICENSED SERVICE(S) is covered by more than one claim of the PATENT RIGHTS or by claims of both the PATENT RIGHTS under this Agreement and “PATENT RIGHTS” under any other license agreement between Company and JHU. The royalty shall not be cumulative based on the number of patents or claims covering a product or service, but rather shall be capped at the rate set forth in Exhibit A.

  • Earned Royalties Subject to of Article 7 hereof, Licensee shall pay to Licensor for the rights granted hereunder a sum equal to one and [*****] of the Net Invoice Value of Trademarked Products Sold by Licensee (the "Royalties"). The Royalties shall be remitted in accordance with Section 7.4 of this Agreement. 6.2

  • Earned Royalty In addition to the annual license maintenance fee, ***** will pay Stanford earned royalties (Y%) on Net Sales as follows:

  • Royalty Rate Licensee shall pay to Licensor three percent (3%) of the first $25 million of Revenues received by Licensee or its Affiliates, and two percent (2%) of all additional Revenues received by Licensee or its Affiliates, subject to reductions pursuant to Sections 4.2.2 and 4.2.3.

  • Royalty Payment For all leased substances that are sold during a particular month, Lessee shall pay royalties to Lessor on or before the end of the next succeeding month. Royalty payments shall be accompanied by a verified statement, in a form approved by Lessor, stating the amount of leased substances sold, the gross proceeds accruing to Lessee, and any other information reasonably required by Lessor to verify production and disposition of the leased substances or leased substances products. Delinquent royalties may be subject to late fees and penalties in accordance with Lessor’s Rules.

  • Royalty Payments (i) Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when delivered to a third party or Affiliate.

  • Royalties 1. Royalties arising in a Contracting State and paid to a resident of the other Contracting State may be taxed in that other State.

  • Net Sales The term “

Time is Money Join Law Insider Premium to draft better contracts faster.